Q2 Interim report
August-October 2021/2022

Promising results published at ESMO

SEK 000s	Q2 21/22	Q2 20/21	May-Oct 21/22	May-Oct 20/21	Full year 20/21
Net sales	268	44	649	384	2,077
Operating profit (loss)	-14,314	-8,285	-26,552	-16,950	-40,181
Profit (loss) for the period	-14,388	-8,208	-26,613	-16,581	-39,482
Earnings per share after dilution	-0.51	-0.29	-0.93	-0.59	-1.39

Significant events during the second quarter

- Biovica has strengthened its management team with the addition of Warren Cresswell, President Americas, with responsibility for the launch of DiviTum®TKa in the USA.
- Update on delay in the FDA process.
- Promising DiviTum®TKa results from the Novartis BioItaLEE study presented at ESMO.
- DiviTum®TKa results from the SWOG study published at Clinical Cancer Research.

Significant events after the end of the period

- Article on the DiviTum®TKa Budget Impact Model published in the Journal of Medical Economics.
- Three studies with DiviTum®TKa presented at SABCS 2021.
- Start of TK IMPACT study at Washington University in St. Louis.

Audiocast:
When: 1 December 2021 at 3 PM CET
Where: https://tv.streamfabriken.com/biovica-international-q2-2021-2022
Phone numbers: SE: +46850558350, DK: +4578150109, UK: +443333009031, US: +16467224904
Broadcast language: in English

CEO's comments

For Biovica, there was much focus during the second quarter on the dialog with the US Food and Drug Administration (FDA). Communication with them has been positive, but the FDA is still struggling to cope with its high workload stemming from the COVID-19 pandemic, which has made it difficult for them to stick to their regular processing time.

In mid-September we announced that we are still waiting for feedback from the FDA in order to be able to submit our updated 510(k) application. The status as of the end of November is that we are still waiting for feedback from the FDA.

It will be possible to launch DiviTum®TKa in the USA once 510(k) approval has been obtained, which we are not expecting before the end of the year. In parallel with that, we are working with the launch in Europe, which is expected to occur after approval and launch in the USA.

One of Biovica's strengths is all of the positive results from clinical trials using the assay. At the world-leading San Antonio Breast Cancer Symposium (SABCS), which will take place during 7–10 December, positive results from studies with DiviTum®TKa will once again be presented. This year, the results from two studies will be presented. One is the clinical study, PROMISE (NCT03281902) performed at the Mayo Clinic and the other is from a collaboration with Carrick Therapeutics.

Researchers involved in the PROMISE study have concluded that TK activity (TKa) prior to treatment with CDK4/6 inhibitor for patients with hormone receptor positive metastatic breast cancer is associated with progression free survival. Concluding that DiviTum®TKa has prognostic value when treating breast cancer patients is an important validation of our test as a potential standard tool for evaluation of the treatment effect on metastatic breast cancer.

Carrick Therapeutics is a pharmaceutical company which, among other things, develops a next generation CDK7 inhibitor, samuraciclib. It is a very interesting pharmaceutical candidate, which has also received Fast Track status from the FDA. Carrick has reached out to Biovica in order to investigate whether DiviTum®TKa could complement their own drug development efforts. Carrick presented the first results of our collaboration at SABCS 2021, showing that, for patients with triple negative breast cancer (TNBC), DiviTum®TKa is able to monitor samuraciclib treatment and is thus useful for monitoring of next generation CDK inhibitors.

It is truly satisfying that more and more pharmaceutical companies are recognizing the value of DiviTum®TKa as they pursue their drug development efforts. Of late, we have noticed an increasing demand for DiviTum®TKa from pharmaceutical companies that develop next generation CDK inhibitors. The next step is to establish more in-depth companion diagnostic (CDx) collaborations, which involves using a diagnostic test as a companion to a therapeutic drug in order to determine its suitability for specific patients.

During the quarter, we also announced that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study were published in the highly ranked scientific journal, Clinical Cancer Research, which is issued by the American Association for Cancer Research (AACR). The strong results support use of DiviTum®TKa as a tool for monitoring disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer and publication in this journal represents important validation of DiviTum®TKa's importance and value.

Promising DiviTum®TKa results from the Novartis BioItaLEE study (287 patients) were also presented at the European Society for Medical Oncology (ESMO) conference during 16-21 September. The results strengthen the potential of DiviTum®TKa as a prognostic, predictive and monitoring biomarker for treatment with the CDK4/6 inhibitor ribociclib from Novartis. It is very promising to see that the results are consistent with prior DiviTum®TKa results with CDK4/6 inhibitor palbociclib from Pfizer.

Washington University in St. Louis has initiated a prospective clinical study aimed at evaluating the clinical utility of DiviTum®TKa for monitoring patients with metastatic breast cancer. It is expected that this study will provide important information on the advantages that DiviTum®TKa offers compared to monitoring using imaging diagnostics and we are looking forward to those results.

One of the most essential cornerstones of a successful commercialization of DiviTum®TKa in the USA is reimbursement from payers. With this in mind, we have created a budget impact model based on DiviTum®TKa's positive clinical results in order to clarify the health economic benefits associated with its use.

The model was presented at the ISPOR conference, and it will now also be presented at SABCS, along with having been published in the Journal of Medical Economics.

The results from this study show that adding DiviTum®TKa to the care regime could offer a net reduction in costs of up to three times its price.

In conjunction with that, we have grown the organization in both Sweden and the USA. During the quarter, we recruited Warren Cresswell as President of the Americas. He has 25 years of experience in the diagnostics industry, bringing with him an extensive network and valuable knowledge of the US reimbursement system. With Warren at the helm in the USA, I am convinced that we will succeed with our launch.

Anders Rylander, CEO

Significant events during the period

Strengthening of the management group
Warren Cresswell has been appointed President Americas and will join the executive management team as of 1 August. He has worked in leading positions for the last 17 years at the Danish diagnostics company, Dako. After that, he worked for 5 years at Prometheus Laboratories, 3 of which were in the role of CEO. It was a start-up diagnostics company that was acquired by Nestlé Health Science. Warren will be able to contribute vast experience in building up and leading commercially successful organizations. Given his 25 years in the diagnostics industry, he also brings with him a comprehensive network and valuable knowledge of the US market in the area of oncology.

Delay in the FDA process
Biovica announced in September that the expected timeline for submitting an updated 510(k) application to the US Food and Drug Administration (FDA) has been lengthened due to a delay in receiving feedback from the FDA.

BioItaLEE presented at ESMO
The study concludes that TKa appears to be a new promising prognostic, predictive and monitoring biomarker in patients with HR positive/HER2 negative metastatic breast cancer treated with ribociclib plus letrozole as first-line therapy. Baseline and dynamic TKa changes provided independent valuable information. Lack of TKa suppression at day 15 indicates enrichment for primary resistance and poor prognosis. TKa rebound at treatment cycle 2, day 1 may indicate early adaptation to ribociclib plus letrozole, while persistent suppression seems to identify patients with sustained inhibition and excellent prognosis.

Results from the SWOG study published at Clinical Cancer Research
DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study were published in the highly ranked scientific journal, Clinical Cancer Research, which is issued by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.

As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 versus 11.2 months and overall survival (OS) was 58 versus 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.

The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA.

Significant events after the end of the period

DiviTum®TKa results published in Journal of Medical Economics

This publication expands on data presented at the ISPOR 2021 meeting. The model's results show that monitoring with DiviTum®TKa may achieve savings of up to three times the extra expense compared to current treatment of patients with metastatic breast cancer.

Care of patients with metastatic breast cancer is a large burden on the budgets of healthcare systems due to cost of therapies, monitoring, and management of side effects. The results from this study show that adding DiviTum®TKa to the care regime could offer a net reduction in costs of up to three times its price. The savings are derived from less use of other monitoring tools such as CT scans and bone scans, and from shortening the amount of time that a patient receives expensive medical treatments, which ultimately prove to be ineffective.

"Our analysis showed that inclusion of DiviTum®TKa could reduce use of a substantial proportion of traditional monitoring. If use of DiviTum®TKa can also predict lack of benefit from costly CDK4/6i therapy and clinicians then act on that information in a timely fashion, our model suggests that this will result in substantial cost savings to patients and health plans," said Scott D. Ramsey from the Fred Hutchison Cancer Research Center.

Three posters on DiviTum®TKa at SABCS

Biovica and Carrick Therapeutics have collaborated on generating TK activity (TKa) data in the phase 1/2A study of samuraciclib (NCT033638939), a first-in-class, oral, selective inhibitor of CDK7 that recently received Fast Track designation from the US Food and Drug Administration (FDA). The study demonstrates the potential association of TKa levels with treatment effect for this next generation CDK inhibitor.
P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

DiviTum®TKa results from the clinical study PROMISE (NCT03281902) conducted at the Mayo Clinic show the association of TKa with progression free survival. The study results are a continuation of the results presented on SABCS 2020. Since then, the study has continued and samples from almost twice as many patients have been tested for TKa. The new results confirm the initial analysis and earlier DiviTum®TKa results – i.e., the usage of DiviTum®TKa as a valuable tool in the evaluation of treatment effect in metastatic breast cancer.
P5-13-22 Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)

Additional results of the healthcare DiviTum®TKa Budget Impact Model show the potential for DiviTum®TKa to substantially reduce the number of CT scans and bone scans used in monitoring women with metastatic breast cancer. Because these scans are both costly and a burden on patients, it reinforces the potential benefit of DiviTum®TKa to healthcare systems and patients. Additionally, the test may enable early identification when a treatment is not effective and therefore enable overall savings of three times the added spend on the DiviTum®TKa test.
P3-03-05 The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer

Start of TK IMPACT study

This is an investigator initiated prospective clinical trial at Washington University in St. Louis to evaluate the clinical utility of Biovica's blood-based biomarker assay, DiviTum®TKa, for monitoring patients with metastatic breast cancer.

The study hypothesis is that incorporation of data from DiviTum®TKa measurements into the treatment monitoring of patients receiving standard first line treatment with CDK 4/6 inhibitors plus endocrine therapies, will be associated with the physicians' decision to change usage and/or timing of other routine monitoring tests such as CT scans and nuclear medicine exams. The study will examine care over time of 55 patients that will be tested regularly with DiviTum®TKa.

Earlier studies have demonstrated that patients with low TKa levels have extended times to disease progression, which enables the possibility to modify and reduce usage of other monitoring exams such as imaging. These other exams represent a burden both on patients and on healthcare costs.

Other

2021 AGM

The Annual General Meeting was held on 31 August 2021 via postal voting.

- The financial statements were adopted, and the Board of Directors and CEO were discharged from liability for the financial year.
- The AGM resolved that no dividends would be distributed to shareholders.
- It was resolved that each Director shall be paid a fee of SEK 200,000 and that the Chairman of the Board shall be paid a fee of SEK 450,000. The Chair of Board committees shall be paid a fee of SEK 50,000 and each committee member shall be paid a fee of SEK 35,000. The fee to the company's auditors is in accordance with the approved invoiced amounts.
- The following Board members were reelected: Lars Holmqvist, Marie-Louise Fjällskog, Maria Holmlund, Ulf Jungnelius, Anders Rylander, Jesper Söderqvist and Henrik Osvald. Lars Holmqvist was re-elected Chairman of the Board.
- Grant Thornton Sweden AB was re-elected as the company's auditor, with Stéphanie Ljungberg as head auditor.
- Guidelines for remuneration to senior executives were adopted.
- Change to the Articles of Incorporation.
- The Board was granted the authority to issue new shares equal to 20% of the current number of shares.
- The AGM resolved to issue 285,000 warrants to employees and 175,000 warrants to the Board of Directors. The warrants shall be transferred on market-based terms and conditions.
- Resolution to issue 165,000 warrants to employees in the USA. The warrants shall be transferred free of charge.

Extraordinary General Meeting 2021

An Extraordinary General Meeting was held on 12 October 2021 via postal voting.

- Annika Carlsson Berg was elected to the Board of Directors.
- Resolution to issue 25,000 warrants to newly elected director. The warrants shall be transferred on market-based terms and conditions.

Comments on the financial performance of the Group

Q2 - Sales and earnings

Net sales for the period amounted to SEK 268 (44) thousand. Second quarter sales are attributable to customers in the research market.

Capitalized work performed by the company for its own use amounts to SEK 649 (880) thousand. The capitalized amount pertains to expenditure associated with developing a new version of DiviTum®TKa for measuring thymidine kinase (TK).

The operating loss for the period was SEK -14,314 (-8,285) thousand.

The increase in costs compared to last year is attributable preparations for the commercialization of DiviTum®TKa.

Net financial items amounted to SEK -47 (98) thousand. Loss after financial items was SEK -14,361 (-8,186) thousand. Loss for the period was SEK -14,388 (-8,208) thousand.

The average number of employees for the period was 25 (21) employees, of which 11 (10) are women.

Q1 and Q2 - Combined sales and earnings

Net sales for the period amounted to SEK 649 (384) thousand. First quarter sales are attributable to customers in the research market. Sales are thus far in accordance with plan. However, the full-year sales are expected to be lower due to the delay in processing of the 510(k) application.

Capitalized work performed by the company for its own use amounts to SEK 1,532 (2,539) thousand. The capitalized amount pertains to expenditure associated with developing a new version of DiviTum®TKa for measuring thymidine kinase (TK).

The operating loss for the period was SEK -26,552 (-16,950) thousand.

The increase in costs compared to last year is attributable preparations for the commercialization of DiviTum®TKa.

Net financial items amounted to SEK -35 (388) thousand. Loss after financial items was SEK -26,587 (-16,562) thousand. Loss for the period was SEK -26,613 (-16,581) thousand.

The average number of employees for the period was 24 (21) employees, of which 11 (10) are women.

Financial position, cash flow and investments

The closing amount for cash & cash equivalents on 31 October 2021 was SEK 117,937 (162,411) thousand. Investments will need to be made over the next few years in order to ensure successful commercialization in the USA and Europe and the current amount of capital secured is expected to be sufficient for approximately two years of operation, including the expected increase in sales.

Capitalized expenditure for development work during the period amounts to SEK 1,532 (2,539) thousand.

Funding

The closing amount for cash & cash equivalents on 31 October 2021 was SEK 117,937 (162,411) thousand. Biovica has secured an ample amount of capital for commercialization in the USA and Europe. It is estimated that the current level of capital is sufficient for approximately two years of operations, including the expected increase in sales. Commercialization in the USA is delayed due to the delay in the FDA process. Thus far, it has not had any impact on the company's capital needs. Neither has it resulted in the need to recognize an impairment loss on the capitalized development costs of DiviTum®TKa.

Related party transactions

During the first half of the year, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid was SEK 102 thousand. Transactions were in accordance with market-based terms and conditions. Additionally, during the time (in September) when she was not a member of the Board of Directors, Annika Carlsson Berg received salary for her work as regulatory advisor.

Warrants and employee stock options

Program	To	Class B shares	Subscription price	Subscription period	Share capital increase
TO4	Board of Directors	150,000	19.50	25 March 2022 - 25 August 2023	10,000.00
TO5	employees	120,000	17.16	25 March 2021 - 25 August 2022	10,000.00
TO6	employees	173,000	45.14	25 March 2022 - 25 August 2023	11,533.33
TO7	Board of Directors	200,000	45.14	25 March 2022 - 25 August 2023	13,333.33
TO8	employees	285,000	70.35	25 March 2023 - 25 August 2024	19,000.00
TO9	Board of Directors	175,000	70.35	1 August 2025 - 30 September 2025	11,666.67
PO1	employees	165,000	70.35	25 March 2023 - 25 August 2024	11,000.00
		1,268,000			**86,533.33**

Warrants and employee stock options

As of 31 August 2021, resolutions had been passed for the TO8 warrant program for employees, TO9 for board members and the PO1 employee stock option plan for employees in the USA. These have been registered, but not yet transferred to employees or the Board of Directors. Warrants will be valued on the date of transfer. The employee stock options in the USA will be earned during the duration of the program. In addition, it was also resolved to issue 25,000 warrants at the Extraordinary General Meeting that was held on 12 October. These have not yet been registered.

Shares

During the period, 50,000 Class B shares were issued due to the TO5 warrants scheme. In conjunction with that, the company received SEK 858,000. As of 31 October 2021, the number of outstanding shares in Biovica was 28,468,372, of which 6,405,190 shares are Class A and 22,063,182 shares are Class B. The total number of votes amounts to 41,278,752.

Reclassification of shares

At the end of each quarter, class A shareholders are offered the opportunity of reclassifying their shares to B shares. Reclassification from Class A to Class B shares lowers the voting power, in that Class A shares carry three votes each and Class B shares carry one vote each. The Class A shares are unlisted, while Biovica's Class B shares are traded on Nasdaq First North Premier Growth Market, Stockholm. A total of 137,670 shares were reclassified on 30 September 2021.

Full year	Class A shares	Class B shares	Total
2021-05-01	6,542,860	21,875,512	28,418,372
Subscription warrants, TO5		50,000	50,000
Reclassification	-137,670	137,670	0
2021-10-31	**6,405,190**	**22,063,182**	**28,468,372**

Policies for preparing the interim report

Accounting policies

This interim report was prepared in accordance with IAS 34, Interim Financial Reporting. The Group applies the Annual Accounts Act, International Financial Reporting Standards (IFRS) that have been adopted by the EU and RFR 1 Additional Accounting Regulations for Groups when preparing the financial statements. The Parent Company applies RFR 2 Accounting for Legal Entities when preparing the financial statements. The applied accounting policies otherwise correspond with those described in the Annual Report for 2020/2021.

New standards and interpretations that enter into force in 2021 and later

As of the date when these financial statements were approved for release, no new standards, revisions or interpretations of existing standards that have not yet entered into force or been published by IASB have been early-adopted by the Group.

Significant risks and uncertainties

There are a number of risks and uncertainties associated with the company's operations, including market, regulatory and financial risks. For a more detailed description of the risks (in Swedish), please see the Annual Report for 2020/2021. There was one COVID-19 risk that materialized during the period, more information on that is provided below. Other risks have not changed compared to what is described in the Annual Report.

COVID-19

There was one COVID-19 risk that materialized during the period. Review of the company's FDA application was delayed by one quarter due to the FDA having reallocated resources to Emergency Use Authorization (EUA) requests for in vitro diagnostics

(IVDs) to address COVID-19. The review was resumed at the end of January. Already at the time when the first feedback was received, the process had taken longer than 90 days, which is the normal processing time for 510(k) applications. And, when the FDA announced that it had resumed its review, it also notified that the process would not follow the ordinary timeframe due to the pandemic.

Because Biovica is still waiting to receive the feedback it needs from the FDA, it has not yet been able to submit its updated application. This means that the scheduled launch of DiviTum®TKa in the USA has been delayed.

It is still unclear when it will be possible to submit the updated application to the FDA, nor is it clear how the long the final review will take once it has been submitted.

Commercialization in the USA has been delayed due to the FDA process taking longer than normal. We have therefore revised our forecasts but have assessed that there is no need to record an impairment loss due to the delay. Thus far, it has not impacted the company's capital needs.

Significant assessments

Assessments and estimates in the financial statements
In preparing the financial statements, the executive management team must make assessments and estimates that affect both the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The actual outcome may deviate from these estimates and assessments.

Estimates and assessments are regularly reviewed. A change in estimates and assumptions is reported in the period when the change is made if it only impacts that period. Otherwise, it is reported in the period when the change is made *and* in future periods if it impact both the current period and future periods.

The most significant uncertainty is associated with intangible assets. Impairment testing is based on a review of the recoverable amount, which is assessed based on the value-in-use of the asset concerned. The company's senior executives calculate future cash flows based on internal business plans and forecasts.

Internal development expenditure for research and development
After capitalization occurs, management monitors that the accounting requirements for development costs are still being met, along with whether there is any indication of impairment to the capitalized expenditure. Should the situation arise whereby the company's financing is not secured, it could result in a write-down requirement on the intangible assets.

Growth and gross margin
The recoverable amount is based on a calculation of the value-in-use by using cash flow forecasts based on budgets that have been approved by the Board of Directors, along with forecasts that stretch over the life of the company's patents. The forecasts are based on the business plan for 2021/2022. Gross margin is calculated based on the product calculation.

Impairment of non-financial assets
In order to assess impairment, management calculates the recoverable amount for each cash-generating unit based on expected future cash flows. It then uses a suitable rate to discount those cash flows to present value. There is uncertainty in assumptions about future operating profit and establishing a suitable discount rate.

Useful life of depreciable assets
At each closing date, management reviews its assessments of the useful life that has been established for each category of depreciable assets, taking into consideration how long the Group expects to use those assets. There is uncertainty in these assessments because of the demand and market acceptance.

Note 1 Financial assets measured at fair value
Of cash and cash equivalents, SEK 12,597 (12,125) is measured at fair value as of 31 October 2021. The recognized change in value is SEK 104 (523) thousand for the first half of the year.

The financial assets stated above consist of investments in funds. For financial instruments that are listed, the quoted prices are used for measurement at fair value (Level 1).

KPIs for the Group

SEK 000s	Q2 21/22	Q2 20/21	May-Oct 21/22	May-Oct 20/21	Full year 20/21
Net sales	268	44	649	384	2,077
Operating profit (loss)	-14,314	-8,285	-26,552	-16,950	-40,181
Profit (loss) for the period	-14,388	-8,208	-26,613	-16,581	-39,482
Capitalized R&D costs	649	880	1,532	2,539	3,560
Capitalized R&D exp., % of op. expenses	-4	-7	-5	-11	-8
Earnings per share, before dilution	-0.51	-0.29	-0.93	-0.59	-1.39
Earnings per share, after dilution	-0.51	-0.29	-0.93	-0.59	-1.39
Cash and cash equivalents at the end of the period	117,937	162,411	117,937	162,411	145,364
Cash flow from operating activities	-12,914	-8,524	-26,177	-15,887	-34,409
Cash flow for the period	-12,988	131,024	-27,439	121,696	104,692
Equity	156,917	202,505	156,917	202,505	182,661
Equity per share	5.52	7.16	5.52	7.16	6.43
Equity ratio (%)	95	95	95	95	95
Average number of employees	25	21	24	21	20

Definitions are the same as those presented in the Annual Report for 2020/2021.

Alternative key performance indicators

Of the KPIs presented above, the only one that is obligatory to report, and which is defined in accordance with IFRS is: Earnings per share, before and after dilution. For the other KPIs, the following are in accordance with IFRS presentation requirements: Profit (loss) for the year, Cash & cash equivalents at the end of the period, Cash flow for the period and Equity.

KPIs	Definition	Reason for using alternative KPIs, which are not defined in accordance with IFRS.
Net sales	Income from goods sold	Shows the demand for the product.
Operating profit (loss)	Profit (loss) before financial items and tax.	Operating profit (loss) is an indication of the company's earnings generated from ordinary operations.
Earnings per share, before and after dilution	Profit (loss) divided by the weighted average number of shares during the period, before and after dilution.	
Cash & cash equivalents and short-term investments	Bank balances and short-term investments	
Cash flow from operating activities	Cash flow before the cash flow from investing activities and financing activities	
Cash flow for the period	Change in cash & cash equivalents for the period not including the effect from unrealized exchange gains and losses.	
Equity per share	Equity divided by the number of shares at the end of the period.	Management uses this KPI to monitor the value of equity per share.
Equity ratio	Equity as a percentage of total assets.	Management uses this KPI because it provides an indication of the company's financial stability.
Average number of employees	The average number of employees is calculated as the average of worked hours during the period divided by normal working hours for the period.	

Consolidated income statement and summary statement of comprehensive income

	Q2 2021/2022	Q2 2020/2021	May-Oct 2021/2022	May-Oct 2020/2021	Full year 2020/2021
Amount in SEK thousands					
Net sales	268	44	649	384	2,077
Other income	74	2,644	142	2,723	3,241
Work performed by the company and capitalized	649	880	1,532	2,539	3,560
Operating income	**991**	**3,567**	**2,324**	**5,646**	**8,878**
Materials cost	-69	-29	-164	-80	-367
Other external costs	-3,212	-3,640	-8,342	-7,608	-15,332
Employee benefit expenses	-10,485	-6,488	-17,269	-12,190	-27,218
Depreciation/amortization	-1,539	-1,695	-3,102	-2,718	-6,142
Operating expenses	**-15,305**	**-11,852**	**-28,876**	**-22,596**	**-49,059**
Operating profit (loss)	**-14,314**	**-8,285**	**-26,552**	**-16,950**	**-40,181**
Financial income	-23	422	0	422	855
Financial expenses	-24	-324	-35	-34	-60
Profit (loss) before tax	**-14,361**	**-8,186**	**-26,587**	**-16,562**	**-39,386**
Income tax	-27	-21	-26	-19	-96
Profit (loss) for the period	**-14,388**	**-8,208**	**-26,613**	**-16,581**	**-39,482**
Consolidated statement of comprehensive income					
Profit (loss) for the period	-14,388	-8,208	-26,613	-16,581	-39,482
Other comprehensive income					
Exchange diff. foreign net invest.	0	0	0	0	0
Other comprehensive income for the period	0	0	0	0	0
Comprehensive income for the period	**-14,388**	**-8,208**	**-26,613**	**-16,581**	**-39,482**
Earnings per share					
Earnings per share, before dilution (SEK)	-0.51	-0.29	-0.93	-0.59	-1.39
Average number of shares, before dilution	28,468,372	28,273,372	28,468,372	28,273,372	28,418,372
Earnings per share, after dilution (SEK)	-0.51	-0.29	-0.93	-0.59	-1.39
Average number of shares, after dilution	29,736,372	29,338,372	29,736,372	29,338,372	29,111,372

Consolidated statement of financial position, in summary

Amount in SEK thousands	2021-10-31	2020-10-31	2021-04-30
ASSETS			
Intangible assets	41,148	43,373	41,869
Machinery, equipment, tools, fixtures and fittings	499	959	704
Right-of-use assets	1,979	2,956	2,312
Deferred tax asset	354	650	499
Total fixed assets	**43,980**	**47,938**	**45,384**
Inventories	1,110	681	527
Accounts receivable	0	345	222
Current receivables	1,992	937	1,153
Cash and cash equivalents	117,937	162,411	145,364
Total current assets	**121,040**	**164,373**	**147,266**
TOTAL ASSETS	**165,020**	**212,312**	**192,650**
EQUITY			
Share capital	1,898	1,885	1,895
Other contributed capital	339,624	335,719	338,758
Reserves	-9	-1	-20
Retained earnings (losses), including loss for the year	-184,597	-135,098	-157,972
Total equity	**156,917**	**202,505**	**182,661**
LIABILITIES			
Lease liabilities	778	1,729	934
Deferred tax liability	308	633	460
Total non-current liabilities	**1,086**	**2,362**	**1,394**
Lease liabilities	1,354	1,310	1,486
Advance payments from customers	1,217	784	1,213
Accounts payable	512	2,332	1,085
Current tax liabilities	50	127	154
Other liabilities	708	1,056	634
Accrued expenses and deferred income	3,175	1,836	4,023
Current liabilities	**7,017**	**7,445**	**8,595**
TOTAL EQUITY AND LIABILITIES	**165,020**	**212,312**	**192,650**

Consolidated statement of changes in equity, in summary

Amount in SEK thousands	Share capital	Other contributed capital	Reserves	Retained earnings	Profit (loss) for the year	Total equity
Opening balance, 1 May 2020	**1,572**	**195,132**	**2**	**-88,171**	**-30,318**	**78,217**
Appropriation in accordance AGM decision				-30,318	30,318	0
New share issue	313	147,737				148,050
Issue costs		-7,151				-7,151
Warrants scheme	10	3,040				3,050
Translation difference			-22			-22
Profit (loss) for the period					-39,482	-39,482
Closing balance, 30 April 2021	**1,895**	**338,758**	**-20**	**-118,489**	**-39,482**	**182,661**
Opening balance, 1 May 2020	**1,572**	**195,132**	**2**	**-88,172**	**-30,318**	**78,216**
Appropriation in accordance AGM decision				-30,318	30,318	0
New share issue	313	147,737				148,050
Issue costs		-7,150				-7,150
Reclassification				-26		-26
Translation difference			-3	-1		-4
Profit (loss) for the period					-16,581	-16,581
Closing balance, 31 October 2020	**1,885**	**335,719**	**-1**	**-118,517**	**-16,581**	**202,505**
Opening balance, 1 May 2021	**1,895**	**338,758**	**-20**	**-118,489**	**-39,482**	**182,661**
Appropriation in accordance AGM decision				-39,482	39,482	0
New share issue	3	855				858
Warrants scheme		11				11
Translation difference			11	-11		0
Profit (loss) for the period					-26,613	-26,613
Closing balance, 31 October 2021	**1,898**	**339,624**	**-9**	**-157,983**	**-26,613**	**156,917**

Consolidated statement of cash flows, in summary

Amount in SEK thousands	Q2 21/22	Q2 20/21	May-Oct 21/22	May-Oct 20/21	Full year 20/21
Cash flow from operating activities before changes in working capital	**-12,925**	**-6,294**	**-23,702**	**-13,882**	**-33,545**
Changes in working capital	11	-2,229	-2,475	-2,005	-864
Cash flow from operating activities	**-12,914**	**-8,524**	**-26,177**	**-15,887**	**-34,409**
Cash flow from investing activities	-685	-914	-1,568	-2,573	-3,560
Cash flow from financing activities	611	140,462	307	140,156	142,661
Cash flow for the period	**-12,988**	**131,024**	**-27,439**	**121,696**	**104,692**
Cash and cash equivalents at the beginning of the period	130,927	31,394	145,362	40,778	40,777
Translation difference, cash and cash equivalents	-2	-8	13	-62	-105
Cash and cash equivalents at the end of the period	117,937	162,411	117,937	162,411	145,364

Parent Company income statement, in summary

Amount in SEK thousands	Q2 2021/2022	Q2 2020/2021	May-Oct 2021/2022	May-Oct 2020/2021	Full year 2020/2021
Net sales	268	44	649	384	2,077
Work performed by the company and capitalized	649	880	1,532	2,539	3,560
Other operating income	74	1,849	142	1,929	2,071
Sales	**991**	**2,773**	**2,324**	**4,851**	**7,708**
Goods for resale	-70	-186	-165	-80	-367
Other external costs	-5,866	-4,512	-12,739	-11,016	-22,119
Employee benefit expenses	-8,291	-5,835	-13,749	-9,573	-22,243
Depreciation/amortization	-1,243	-1,399	-2,494	-2,106	-4,887
Operating expenses	*-15,469*	*-11,932*	*-29,147*	*-22,776*	*-49,615*
Operating profit (loss)	**-14,479**	**-9,160**	**-26,823**	**-17,925**	**-41,907**
Other interest income and similar items	-1	137	43	468	759
Interest expenses and similar items	-13	-1	-13	-1	-1
Profit (loss) before tax	**-14,493**	**-9,024**	**-26,792**	**-17,459**	**-41,150**
Appropriations	**0**	**0**	**0**	**0**	**1,146**
Tax on profit for the period	0	0	0	0	0
Profit (loss) for the period	**-14,493**	**-9,024**	**-26,792**	**-17,459**	**-40,004**

Comprehensive income (loss) equals the loss for the period.

Parent Company balance sheet, in summary

Amount in SEK thousands	2021-10-31	2020-10-31	2021-04-30
ASSETS			
Intangible assets	41,148	43,373	41,869
Machinery, equipment, tools, fixtures and fittings	499	959	704
Financial assets	2,232	1,228	2,217
Total fixed assets	**43,880**	**45,560**	**44,790**
Inventories	1,110	681	527
Current receivables	1,821	1,319	1,511
Cash and cash equivalents	115,706	160,319	142,920
Total current assets	**118,637**	**162,319**	**144,958**
TOTAL ASSETS	**162,517**	**207,879**	**189,748**
EQUITY			
Total restricted equity	29,108	29,593	29,105
Total non-restricted equity	127,030	171,964	152,956
Total EQUITY	**156,138**	**201,557**	**182,061**
LIABILITIES			
Total current liabilities	6,378	6,322	7,686
Total LIABILITIES	**6,378**	**6,322**	**7,686**
TOTAL EQUITY AND LIABILITIES	**162,517**	**207,879**	**189,748**

This report has been subject to an overall review by the company's auditor.

Board of Directors' assurance
The Board of Directors and CEO hereby certify that this interim report provides a true and fair summary of the Parent Company's and the Group's operations, earnings and financial position as well as describing any significant risks or uncertainties faced by the Parent Company or any of the companies belonging to the Group.

Uppsala 1 December 2021

Lars Holmqvist
Chairman of the Board

Annika Carlsson Berg
Board Member

Marie-Louise Fjällskog
Board member

Maria Holmlund
Board member

Jarl Ulf Jungnelius
Board member

Henrik Osvald
Board member

Anders Rylander
Board member, CEO

Jesper Söderqvist
Board member

Calendar

Interim Report for Q3: November-January 2021/ 2022	15 March 2022
Interim Report for Q4: May-July 2021/2022	16 June 2022

For more information, please contact:

Anders Rylander, CEO
Phone: +46 (0)18- 44 44 835
E-mail: anders.rylander@biovica.com

Cecilia Driving, EVP CFO
Phone +46 (0)73 125 92 47
E-mail: cecilia.driving@biovica.com

Biovica International AB (publ), 556774-6150
Dag Hammarskjölds väg 54B
752 37 Uppsala
+46 (0)18- 44 44 830

Biovica – Treatment decisions with greater certainty

Biovica develops and commercializes blood-based biomarker assays for evaluating the effect of cancer treatments. Biovica's assay DiviTum®TKa measures cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum®TKa is evaluation of the treatment effect on metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum®TKa has CE marking and it is registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 (0)8- 528 00 399. For more information, please visit www.biovica.com.

Biovica International AB (publ)

Introduction

We have reviewed the condensed interim financial statements for Biovica International AB (publ) and its subsidiary as of 31 October 2021 and the six-month period ending on that date. The Board of Directors and CEO are responsible for the preparation and fair presentation of this interim financial information in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. Our responsibility is to express a conclusion on these interim financial statements based on our review.

Scope and focus of the review

We conducted our review in accordance with International Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity.* A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review has a different focus and is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (ISAs) and generally accepted auditing standards. Consequently, it does not enable us to obtain assurance that we would become aware of all significant matters that might otherwise have been identified in an audit. The conclusion based on a review does not therefore offer the same level of assurance as an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements have not in all materially respects been prepared in accordance with IAS 34 and the Annual Accounts Act for the Group and in accordance with the Annual Accounts Act for the Parent Company.

Uppsala 1 December 2021

Stéphanie Ljungberg
Authorized Public Accountant